Driving Amazing R&D Progress

09.02.14 | By

We are on the cusp of amazing progress in U.S. biopharmaceutical research and development, but without policies that help attract and retain research-based companies and partnerships to help bring new medicines to patients, we run the risk of losing our country’s competitive advantage.

One Stop for Innovation: PhRMA’s New Innovation.org

08.26.14 | By

It’s likely many of us have paused to think about what life would have been like in a bygone time and felt thankful for the modern comforts we enjoy, from refrigeration to cell phones. When looking at the progress we’ve made and the comforts we enjoy, medical innovation should be at the top of the list. Over the past 100 years, life expectancy has surpassed 80 years, devastating diseases have been eradicated and quality of life has dramatically improved.

Modi’s New Era Has Begun

07.31.14 | By

Following up on our May post, the next chapter in the rebuilding of the U.S. – India relationship has begun, as U.S. Secretary of State John Kerry and Secretary of Commerce Penny Pritzker are in India to meet with their counterparts in the new Indian government. Secretary Kerry will partake in the fifth U.S.-India Strategic Dialogue and also meet with Prime Minister Modi, the first meetings to occur between high-ranking officials from the U.S. and India since Modi’s election in May.

Weighing-in on the Cost and Value of Innovation

07.31.14 | By

Earlier this week, PhRMA participated in the Wall Street Journal’s first tweet chat hosted by Ed Silverman, who spearheads the publication’s blog, Pharmalot.

World Hepatitis Day: Driving Momentum to Help Patients

07.29.14 | By

For the millions of patients battling hepatitis C, World Hepatitis Day will hopefully be a day that is only read about in history books.

Now, more than ever before, there is great hope on the horizon as new and forthcoming medicines can provide nearly all patients fighting this disease with a cure. 

Assessing the Long-Term Value of Hepatitis C Treatments

07.25.14 | By

The current debate regarding the cost of new and forthcoming hepatitis C treatments has brought to light a long-standing discussion about the cost and value of innovative new medicines.

Energy and Commerce Health Subcommittee Explores Need for More Robust Communication about Real World Uses of Medicines

07.25.14 | By

As part of the 21st Century Cures initiative, the House Energy and Commerce Subcommittee on Health discussed barriers to evidence development and communication for medicines and devices.

What the NY Times Got Wrong About Biopharmaceutical Innovation

07.24.14 | By

A recent article in the New York Times once again missed the mark when it comes to reporting on the great promise in the biopharmaceutical pipeline.

New Cancer Medicines Driving Value for Patients

07.22.14 | By

If conventional wisdom says that spending on new cancer medicines is at “unsustainable” levels, and a demonstration project designed to address this leads to increased spending on new cancer medicines and reduced total medical costs, then what happens to conventional wisdom? That’s one question you might be left with after reading the surprising results of the much-anticipated study by Lee Newcomer, MD from United Healthcare and two cancer centers. The study was designed to cut cancer treatment costs, and to do so by reducing use of new cancer medicines.

Week in Review: The Fight for Innovation and Access

07.18.14 | By

Our president and CEO John Castellani asked, “What would happen if the pace of medical innovation in the U.S. slowed or halted altogether?” It’s a scary thought when you consider that without research and development (R&D), the treatments patients have come to depend on and hope to see in the future would not and will not exist. As a result, this week we highlighted a few extraordinary advancements and discussed what it means when patients do not have access to necessary treatments.

Pages

Subscribe to RSS - Opinion